Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Aug 22, 2024 12:13pm
60 Views
Post# 36191960

RE:RE:RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

RE:RE:RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

August 19, 2024 - The U.S. BIOSECURE Act proposes to ban five P.R.C.-based biotech companies from operating in the United States – and potentially to ban other “biotechnology companies of concern” – amid a backdrop of concerns that the Chinese government might obtain U.S. IP and exploit Americans’ genomic data. The prospect of this legislation being passed into law is already leading to meaningful shifts in market behavior. We have seen major strategy reconsiderations by both U.S. and P.R.C.-based biotechs in reaction to the proposed legislation, and some life sciences companies are already including in their contracts with PRC-based biotechs contingency language which hedges against the prospect of the BIOSECURE Act. 

Particularly in this U.S. Presidential election year, there has been a bipartisan consensus in the U.S. Congress about the need to be “tough on China,” and a concern about the increasing reliance by U.S. biotechs on P.R.C.-based biotechs for R&D and manufacturing. However, the BIOSECURE Act is still only a proposal. Supporters of the BIOSECURE Act have tried to pass it before and failed, and they are still modifying the text to find a way to overcome the bicameral hurdle (the House and Senate need to pass identical versions) this year. As a result, the BIOSECURE Act is likely to remain a live issue until Congress adjourns at the end of the year, regardless of the winner of November’s U.S. elections. 

Current intelligence indicates the sponsors of the BIOSECURE Act will seek to advance the draft legislation as a stand-alone proposal.  A stand-alone bill would be likely to achieve strong support in the U.S. House of Representatives, but would be expected to face greater challenges in the U.S. Senate.  However, if the BIOSECURE Act is going to become law this year, the legislation is most likely to be attached to a broader legislative package, such as the U.S. National Defense Authorization Act (NDAA), an annual bill to fund the U.S. military.


https://goodlifesci.sidley.com/2024/08/19/how-when-and-if-the-u-s-biosecure-act-is-likely-to-become-law/

<< Previous
Bullboard Posts
Next >>